Real-World Implementation of Treatment Intensification After Methotrexate in Rheumatoid Arthritis in the Context of Treat-to-Target Recommendations: Insights From Japan’s Claims Data
Clicks: 1
ID: 314702
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #36 of 36 articles by views in modern rheumatology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: To describe real-world treatment patterns in Japanese patients with rheumatoid arthritis, focusing on intensification after methotrexate and prescribing patterns of methotrexate and glucocorticoids, in the context of treat-to-target strategy. METHODS: This was a retrospective cohort study using claims database. Adults with rheumatoid arthritis who initiated methotrexate were included and classified by treatment intensification within 210 days (6 months, as per the guideline, plus a 30-day grace period) into three groups: (1) intensified to conventional synthetic disease-modifying antirheumatic drugs, (2) intensified to biologic or targeted synthetic disease-modifying antirheumatic drugs, or (3) remained on methotrexate monotherapy. Methotrexate and glucocorticoid dose transitions were visualised using Sankey diagrams. RESULTS: Of 21,734 patients, 13,784 (63.4%) remained on methotrexate monotherapy and 4,949 (22.8%) received intensification (63.8% intensified with synthetic disease-modifying antirheumatic drugs and 34.8% with biologic or targeted synthetic disease-modifying antirheumatic drugs). In the intensified subgroups, 40% used glucocorticoids for >90 days, and 80% had a daily dose >5 mg; approximately 30% received a methotrexate dose <6 mg when transitioned to second-line therapy. CONCLUSIONS: The low intensification rate within 6 months, predominance of synthetic disease-modifying drugs, insufficient methotrexate dose escalation, and long-term use of glucocorticoids suggest a gap between real-world clinical practice and guideline recommendations.
| Reference Key |
openalex_W7162126807
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Tsutomu Takeuchi, Hisaaki Isaji, Yi Piao, Susan Song, Mahiro Tani |
| Journal | modern rheumatology |
| Year | 2026 |
| DOI |
10.1093/mr/roag046
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.